Patients with diabetic macular edema or wet age-related macular degeneration treated with UBX1325 showed positive safety results and “rapid” improvements in several key metrics, according to a press release from Unity Biotechnology.
UBX1325, a small molecule inhibitor of Bcl-xL, was assessed in a phase 1 clinical study to determine its safety profile. The therapy is being developed to potentially aid patients in whom anti-VEGF therapy is no longer helpful.
The first-in-human, open-label, single-ascending dose study enrolled 12 patients with advanced DME or wet AMD. UBX1325